Lin Yang

Associate

Hong Kong

+ 852 2241 2575

Email
vcard

Areas of Work

FCPA/Anti-Corruption, Independent & Internal Investigations, Commercial Litigation, International Arbitration

Languages

Mandarin Chinese

Cantonese

Overview

Lin Yang is a highly experienced attorney with a strong focus on international regulatory compliance and litigation. She has represented multinational corporations across diverse industries in both cross-border litigation and FCPA/internal investigations matters. Lin is particularly skilled in advising clients on compliance issues related to their operations in China and Southeast Asia, including compliance with the FCPA, US securities laws, and internal control policies.

Her practice involves conducting internal investigations in China, advising clients on cross-border litigation matters, and conducting compliance audits on Sino-foreign joint ventures. Lin has also provided remediation recommendations to clients in the aftermath of compliance audits. Lin has extensive experience representing Chinese companies in U.S. litigation and providing legal advice to Chinese companies on U.S. regulatory compliance. She is well-regarded for her comprehensive understanding of the legal and business landscapes in China and Southeast Asia, making her a valuable resource for multinational corporations operating in the region.

District of Columbia
New York
PRC Non-practicing license
Registered Foreign Lawyer, Hong Kong

J.D., George Mason University School of Law
B.A., Sun Yat-Sen University School of Law

Representative Matters

Conducted a FCPA internal investigation for a leading global engineering and logistics company.
Conducted third party due diligence reviews for more than 40 resellers/agents in Mainland China.
Assisted a leading international accounting firm with preparation of expert witness evidence on compliance with PRC State Secrets Law and directives issued by the relevant supervising government organ.
Represented a Chinese manufacturer in commercial litigation in Washington state court and federal court, successfully defeated adverse party’s motion to dismiss certain claims.
Conducted a proactive compliance audit of Sino-foreign joint venture and its distributors on behalf of a large US pharmaceutical company.
Represented a large US pharmaceutical company in relation to a number of FCPA internal investigations across various cities in China, including issues related to T&E, inaccurate books and records, improper payments to health care professionals, and high risk third party transactions.
Represented a global hospitality business in relation to a number of FCPA, fraud, and immigration law related internal investigations in Malaysia.
Conducted internal investigations for one of the largest MNC pharmaceutical companies in response to the DOJ’s inquiry regarding certain FCPA issues related to its sales practices.

Speaking Engagements

"Corporate Internal Control and Investigation," 13th China International Anti-Corruption Compliance Summit 2024, May 29, 2024
"Panel Discussion: Corporate Internal Control and Investigation," 13th China International Anti-Corruption Compliance Summit 2024 (Shanghai), May 29, 2024